🔗 Share this article

While America continues making sweeping changes to its immunization guidelines, a particular individual appears in a surprising turn: Høeg, a US-based physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots throughout the pandemic and has focused upon alleged deaths following Covid vaccination in her recent tenure at the Food and Drug Administration.

Proposed Shifts to Pediatric Vaccine Schedule

Agency leaders planned to unveil sweeping changes to the pediatric immunization program in December, aligning the US with the Danish immunization schedule, it is understood – a major change that would put the US at odds with much of the world with little proof for benefit. This reveal has been postponed until the coming year.

Rather than the top vaccines chief, Høeg is scheduled to speak at the gathering. She was just designated acting director of the FDA’s CDER, the fifth appointee to head the division this year.

Consolidating Power at the Regulatory Body

This interim role could signify a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon rolling back already-approved vaccines at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric shot schedules in the US to become more in line with Denmark, a nation with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

So far comments, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Background

The appointee has no obvious experience in pharmaceutical research, approval processes or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She appears not to have the necessary background” for running the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in leading a sizeable institution. She is not an expert in drug approvals.”

Previous commissioners of CBER would “grasp laws and regulations and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that prior appointees who headed the center have had.”

CDER has an immense workload at the FDA, Woodcock emphasized.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those need to be looked after,” she noted. “The area you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a major leadership component to the position, which supervises more than 5,000 personnel. “It is a massive leadership role, if you do it right,” she said.

Official Statement and Contentious Initiatives

Regarding inquiries about Høeg’s fitness for the role and whether this selection signifies more teamwork among regulatory chiefs on vaccines, a press secretary said that the “inquiries are based on inaccurate presumptions”.

“This background is consistent with the functions of her job,” the representative stated, noting the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial one-day medication authorization process that reportedly worried her predecessors. “How are these therapies being picked for this expedited pathway? Who makes the choices?” Howard asked. “There is a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards laxer rules of all drugs, with the exception of immunizations.”

Public Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if problematic, past, some experts have noted. She authored a research paper using non-validated volunteer-provided data to estimate the incidence of myocarditis following Covid immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the current administration included revising guidelines for novel immunizations and halting “non-essential” vaccines, she said post-election on a podcast. At the agency, Høeg has allegedly floated the idea of excluding young men from receiving Covid vaccinations.

“She’s an thorough true believer who starts off with her beliefs and reverse-engineers to accommodate the science in a extremely deceptive, dishonest manner,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow contrarians, {like|